The RegMed Forum 2027 From pluripotent stem cells (PSCs) to Next-Generation Gene and Cell Therapies highlights the latest advances in pluripotent stem cell-based gene and cell therapies and addresses key challenges in their clinical translation and fosters the collaboration between academia, industry, start-ups, and clinicians to accelerate the development and implementation of next-generation regenerative therapies.
Human pluripotent stem cells (hPSCs) have become a key platform for regenerative medicine, enabling disease modeling, drug discovery, and the development of advanced gene- and cell-based therapies. Rapid progress in stem cell technologies is accelerating the generation, differentiation, and clinical translation of hPSC-derived products.
The RegMed Forum 2027 will showcase cutting-edge developments in hPSC-based regenerative therapies, covering novel therapeutic approaches, cell differentiation and maturation, GMP-compliant manufacturing, quality control, and regulatory aspects. Special emphasis will be placed on strategies to improve the safety, efficacy, scalability, and accessibility of next-generation therapies.
Bringing together experts from academia, start-ups, and industry, the Forum aims to promote interdisciplinary exchange on the clinical
...
afficher plus
The RegMed Forum 2027 From pluripotent stem cells (PSCs) to Next-Generation Gene and Cell Therapies highlights the latest advances in pluripotent stem cell-based gene and cell therapies and addresses key challenges in their clinical translation and fosters the collaboration between academia, industry, start-ups, and clinicians to accelerate the development and implementation of next-generation regenerative therapies.
Human pluripotent stem cells (hPSCs) have become a key platform for regenerative medicine, enabling disease modeling, drug discovery, and the development of advanced gene- and cell-based therapies. Rapid progress in stem cell technologies is accelerating the generation, differentiation, and clinical translation of hPSC-derived products.
The RegMed Forum 2027 will showcase cutting-edge developments in hPSC-based regenerative therapies, covering novel therapeutic approaches, cell differentiation and maturation, GMP-compliant manufacturing, quality control, and regulatory aspects. Special emphasis will be placed on strategies to improve the safety, efficacy, scalability, and accessibility of next-generation therapies.
Bringing together experts from academia, start-ups, and industry, the Forum aims to promote interdisciplinary exchange on the clinical translation of advanced therapeutic approaches, including ATMPs, advanced medical devices, and combined products. The Forum seeks to encourage strategic partnerships and accelerate the translation of scientific discoveries into clinical and commercial applications. Through scientific sessions and networking opportunities, participants will explore current challenges and future opportunities in the rapidly evolving field of gene- and cell-based therapies.
An accompanying industry exhibition will provide a platform for companies and technology providers to present innovative tools, services, and therapeutic solutions.
Further information about the programme you can find here.
For further information about our co-organizers, please visit their websites:
We are delighted to have the support of biotechnologieverbund berlin-brandenburg e.V. again this year.
By purchasing this ticket:
I declare that I would like to participate in the RegMed Forum and give my consent for my data to be collected and stored for the purpose of organising this event. The BIH may use my email address to send me announcements about future BIH events.
I acknowledge that, by registering to this event, BIH and its representatives have permission to photograph, video, or otherwise capture the images of me, and to make recordings of my voice. I further understand that BIH and its representatives have the right to reproduce, use, exhibit, display, broadcast and distribute, and create derivative works of these images and recordings in any media now known or later developed as well as for promoting, publicizing or explaining BIH and its activities and for administrative, educational or research purposes. I acknowledge that BIH owns all rights to the images and recordings. According to the GDPR, I can revoke my consent at any time without giving reasons.
afficher moins
